SiBone (NASDAQ:SIBN) Posts Quarterly Earnings Results, Beats Expectations By $0.06 EPS

SiBone (NASDAQ:SIBN) announced its earnings results on Monday. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.06, Zacks reports. SiBone had a negative net margin of 12.83% and a negative return on equity of 14.20%. SiBone updated its FY 2025 guidance to EPS.

SiBone Trading Down 0.6%

Shares of SIBN stock traded down $0.09 on Monday, reaching $15.68. 699,415 shares of the company’s stock were exchanged, compared to its average volume of 423,326. The company’s fifty day simple moving average is $15.23 and its 200 day simple moving average is $16.55. SiBone has a 52 week low of $11.70 and a 52 week high of $20.05. The company has a current ratio of 8.38, a quick ratio of 7.00 and a debt-to-equity ratio of 0.21. The stock has a market capitalization of $676.44 million, a PE ratio of -28.00 and a beta of 0.81.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. Truist Financial decreased their price objective on SiBone from $22.00 to $20.00 and set a “buy” rating on the stock in a research report on Wednesday, October 15th. Wall Street Zen downgraded SiBone from a “buy” rating to a “hold” rating in a research report on Saturday, August 9th. Cantor Fitzgerald set a $25.00 price target on SiBone and gave the stock an “overweight” rating in a research report on Monday, August 11th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SiBone in a research note on Wednesday, October 8th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $23.00.

Insiders Place Their Bets

In other news, CFO Anshul Maheshwari sold 3,461 shares of the company’s stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $15.57, for a total value of $53,887.77. Following the transaction, the chief financial officer directly owned 214,445 shares in the company, valued at approximately $3,338,908.65. This represents a 1.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Michael A. Pisetsky sold 3,329 shares of the firm’s stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $15.64, for a total transaction of $52,065.56. Following the completion of the transaction, the senior vice president directly owned 258,352 shares in the company, valued at $4,040,625.28. This represents a 1.27% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 32,009 shares of company stock worth $485,884. Insiders own 3.90% of the company’s stock.

Institutional Investors Weigh In On SiBone

Large investors have recently added to or reduced their stakes in the stock. State of Wyoming bought a new position in SiBone in the 2nd quarter worth about $55,000. Canada Pension Plan Investment Board bought a new stake in shares of SiBone during the second quarter valued at approximately $68,000. Tower Research Capital LLC TRC boosted its holdings in shares of SiBone by 198.8% in the second quarter. Tower Research Capital LLC TRC now owns 4,897 shares of the company’s stock valued at $92,000 after purchasing an additional 3,258 shares during the period. State of Tennessee Department of Treasury bought a new position in SiBone in the second quarter worth approximately $137,000. Finally, Dynamic Technology Lab Private Ltd bought a new position in SiBone in the first quarter worth approximately $225,000. 98.11% of the stock is owned by hedge funds and other institutional investors.

About SiBone

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.